Key points from article :
Alkahest Inc. announces top-line data from two Phase 2 studies of AKST4290.
AKST4290 was found to be safe and well tolerated.
Gains in visual acuity for both treatment naïve and treatment refractory patient groups.
Demonstrates feasibility of an oral agent to treat wAMD.
Current treatments for wAMD involve regular intravitreal injections of anti-VEGF therapies.
AKST4290 is an orally administered CCR3 inhibitor that blocks the action of eotaxin
May slow the hallmark inflammation and neovascularization of wet AMD and other age-related diseases.
